A long-overlooked Alzheimer’s symptom just got its first targeted drug. Axsome Therapeutics has secured U.S. FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s disease.
This is a big deal. Not because it’s another Alzheimer’s drug—but because it targets one of the most disruptive, under-treated symptoms.
Alzheimer’s isn’t just memory loss. Up to 76% of patients experience agitation—ranging from restlessness to aggression. It’s one of the biggest drivers of:
Until now, there were no specifically approved therapies for this condition. Auvelity changes that.
Auvelity isn’t built like traditional CNS drugs. It works through a dual mechanism:
Its second component, bupropion, plays a supporting role:
The result: a novel pathway targeting agitation biology, not just symptoms.
The approval is backed by two key Phase 3 studies:
Translation: it works fast and lasts longer than placebo.
One of the biggest concerns in this population is tolerability. Auvelity held up well:
That’s rare in elderly, neurologically fragile populations.
This wasn’t a slow approval. The FDA gave Auvelity:
Both are reserved for drugs that show meaningful improvement over existing care. That tells you how big the unmet need is.
Auvelity isn’t new to the market. It was already approved in 2022 for:
And it’s been used in:
This de-risks adoption. Clinicians already know the drug.
Axsome isn’t chasing crowded targets. It’s picking neglected ones.
Their playbook:
According to CEO Herriot Tabuteau, this approval reinforces their focus on serious brain health conditions. And they now own a unique position in Alzheimer’s care.
This approval opens a new category—but questions remain:
One thing is clear: The Alzheimer’s treatment landscape is no longer just about slowing decline—it’s about managing the symptoms that break patients and caregivers first.